Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

611
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
611

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study.

EClinicalMedicine·2026
Same author

Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Cardiovascular disease risk among long-term testicular cancer survivors following contemporary cisplatin-based chemotherapy.

Journal of the National Cancer Institute·2026
Same author

CT online adaptive radiotherapy is associated with dosimetric and acute toxicity improvements in prostate cancer treatment.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Stereotactic magnetic resonance imaging-guided adaptive radiotherapy: a pooled analysis of a master prospective trial.

Journal of the National Cancer Institute·2025
Same author

Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer.

Journal of the National Cancer Institute·2025

Related Experiment Video

Updated: Apr 26, 2026

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

7.3K

Interstitial photodynamic therapy for prostate cancer: a developing modality.

Neil E Martin1, Stephen M Hahn

  • 1Department of Radiation Oncology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, 3400 Spruce Street, 2 Donner, Philadelphia, PA 19104-4283, USA.

Photodiagnosis and Photodynamic Therapy
|July 23, 2014
PubMed
Summary
This summary is machine-generated.

Photodynamic therapy (PDT) shows promise for prostate cancer, offering an alternative to surgery or radiation. Further research is needed to optimize this technique for widespread clinical use.

More Related Videos

An In Vitro Approach to Photodynamic Therapy
04:53

An In Vitro Approach to Photodynamic Therapy

Published on: August 17, 2018

10.7K
An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
11:04

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

Published on: January 13, 2023

2.8K

Related Experiment Videos

Last Updated: Apr 26, 2026

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

7.3K
An In Vitro Approach to Photodynamic Therapy
04:53

An In Vitro Approach to Photodynamic Therapy

Published on: August 17, 2018

10.7K
An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
11:04

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

Published on: January 13, 2023

2.8K

Area of Science:

  • Oncology
  • Biomedical Engineering
  • Photochemistry

Background:

  • Radical prostatectomy and radiotherapy are standard treatments for early prostate cancer but have side effects and failure rates.
  • Photodynamic therapy (PDT) is being explored as an alternative for primary and recurrent prostate cancer.
  • Effective PDT requires precise dosimetry, considering photosensitizer concentration, tissue oxygenation, and light fluence.

Purpose of the Study:

  • To review preclinical and clinical research on photodynamic therapy for prostate cancer.
  • To identify areas for future research to establish PDT as a practical treatment option.

Main Methods:

  • Review of preclinical studies on prostate tissue optical characteristics and canine PDT models.
  • Analysis of limited clinical trial data on PDT for prostate cancer.
  • Evaluation of photosensitizer concentration, tissue oxygenation, and light fluence in PDT.

Main Results:

  • Canine studies demonstrated glandular epithelium necrosis (1-17mm depth) and atrophy, with urinary complications linked to transurethral light.
  • Preclinical research highlighted variability in prostate tissue optical properties.
  • Available clinical data suggest PDT is tolerable for patients with primary and recurrent prostate cancer.

Conclusions:

  • Photodynamic therapy is a potentially tolerable treatment for prostate cancer.
  • Further research is essential to refine dosimetry and address limitations before PDT can be widely adopted.
  • Optimizing PDT parameters is crucial for successful clinical application in prostate cancer treatment.